UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

__________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June 17~~August 13, 2025

__________________________________

Immuneering Corporation

(Exact name of Registrant as Specified in Its Charter)

__________________________________


Delaware	001-40675	26-1976972
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

245 Main St.

Second Floor

Cambridge, MA 02142

(Address of principal executive offices) (Zip Code)

(617) 500-8080

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.001 per share

IMRX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~June 17~~August 13, 2025, Immuneering Corporation (the "“Company~~", "we", "us" and "our"~~”) announced ~~interim data from~~ its ~~ongoing~~financial ~~Phase~~results 2afor ~~clinical~~the ~~trial~~quarter ~~arm~~ended ~~evaluating~~June 30, ~~atebimetinib~~2025 ~~(formerly~~and ~~known~~provided asoperational ~~IMM-1-104),~~updates. aThe ~~once-daily~~full ~~oral~~text ~~mitogen-activated~~of ~~protein~~the ~~kinase~~press ~~kinase~~release ~~("MEK")~~issued ~~inhibitor,~~ in ~~combination~~connection with ~~modified Gemcitabine/nab-Paclitaxel ("mGnP") in first-line pancreatic cancer patients (~~the ~~"mGnP~~announcement ~~Arm"), which~~ is ~~part~~furnished ofas ~~Company's~~Exhibit ~~ongoing Phase~~ 99.1~~/2a~~ ~~clinical~~to ~~trial~~this ofCurrent ~~atebimetinib~~Report inon ~~patients~~Form ~~with advanced RAS~~8-K ~~and/or~~(the ~~RAF-mutant~~“Current ~~solid tumors~~Report”).

The ~~Company~~information ~~announced~~in ~~that,~~this asItem of2.02 ~~a cutoff date~~ of ~~May~~this 26Current Report, ~~2025~~including ~~(the~~Exhibit ~~"Cutoff Date")~~99.1, ofis ~~the~~intended 36to ~~response~~be ~~evaluable~~furnished ~~patients~~and inshall ~~the~~not ~~mGnP~~be ~~Arm~~deemed ~~dosed~~“filed” atfor ~~the~~purposes ~~240~~of mgSection or18 ~~320~~of mgthe ~~once-daily~~Securities ~~dose~~Exchange ~~level~~Act of ~~atebimetinib in combination with mGnP~~1934, ~~one~~as ~~patient~~amended ~~achieved a complete response, 13 patients achieved a partial response~~ (~~with~~the ~~four~~“Exchange ~~such patients pending response confirmation at a subsequent scan~~Act”), 15or ~~patients~~otherwise ~~achieved~~subject ~~stable~~to ~~disease,~~the ~~and~~liabilities ~~seven~~of ~~patients~~that ~~showed progressive disease~~section, ~~collectively~~nor ~~representing~~shall anit ~~interim~~be ~~81%~~deemed ~~(29/36)~~incorporated ~~disease~~by ~~control~~reference ~~rate~~in ~~("DCR")~~any ~~and~~filing anunder ~~interim~~the ~~39%~~Securities ~~(14/36)~~Act ~~overall~~of ~~response~~1933, ~~rate~~as ~~("ORR")~~amended, inor ~~each~~the ~~case~~Exchange asAct, ~~measured~~except byas ~~the~~expressly ~~Response~~provided ~~Evaluation~~by ~~Criteria~~specific reference in ~~Solid~~such ~~Tumors~~a ~~("RECIST") method~~filing.

~~The~~Item ~~Company~~9.01. ~~also~~Financial ~~announced~~Statements ~~that, as of the Cutoff Date, 94% overall survival ("OS")~~ and 72% progression free survival ("PFS") were observed in the intent-to-treat population of 34 patients dosed at the 320 mg once-daily dose level of atebimetinib in combination with mGnP (the "320 mg ITT Population"), in each case with a median follow-up time of six monthsExhibits. ~~As of the Cutoff Date, neither the median OS nor the median PFS of the 320 mg ITT Population had been reached.~~

The Company also announced that, as of the Cutoff Date, atebimetinib in combination with mGnP was observed to be generally well tolerated. As of the Cutoff Date, Grade ≥ 3 treatment-emergent adverse events (~~"TEAEs"~~d) observed in 10% or greater of patients in the 320 mg ITT Population were limited to Anemia (six patients or 18%) and Neutropenia (five patients or 15%). No Grade 5 TEAEs were observed in this subset of the patient population.Exhibits

~~Also~~The onfollowing ~~June~~exhibits ~~17,~~relate ~~2025,~~to ~~the~~Item ~~Company announced that additional data from the Phase 2a portion of the Company’s atebimetinib Phase 1/2a trial was expected in the fourth quarter of 2025~~2.02, ~~and~~which ~~that~~shall ~~the~~be ~~Company~~deemed ~~planned, pending regulatory feedback expected in the fourth quarter of 2025,~~ to ~~initiate~~be ~~a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026~~furnished, and tonot ~~initiate additional clinical trial combination arms evaluating atebimetinib also in 2026.~~filed:

Forward-Looking Statements


Exhibit No.						Description
99.1						Press Release issued on August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

This Current Report on Form 8-K (this “Current Report”) contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding the design and conduct of the Phase 1/2a clinical trial of atebimetinib, the timing of a planned pivotal trial evaluating atebimetinib with mGnP, plans for additional atebimetinib combination therapy trials, the timing and substance of regulatory feedback, and the timing of release of additional data from the ongoing Phase 1/2a clinical trial of atebimetinib.

These forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 20, 2025, our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025 and filed with the SEC on May 5, 2025 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNEERING CORPORATION
Date: June 17, 2025	By:	/s/ Michael D. Bookman
Date: August 13, 2025	By:	/s/ Benjamin J. Zeskind
		Name: Michael D. Bookman
		Name: Benjamin J. Zeskind, Ph.D.
		Title: Chief Legal Officer and Secretary
		Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)

Filing Compare · Immuneering Corp